BANC Investors Have Opportunity to Join Banc of California, Inc. Fraud Investigation with SBS Law

Banc of California (BANC) reported Q2 2026 results during an earnings call, citing a net loss available to common of $251.3 million ($-1.61/share) tied to nonrecurring balance sheet restructuring. The company sold $2.3 billion of lower-yield securities and $827 million of select loans to held-for-sale, retired $385 million of subordinated debt, and guided NIM to 3.30% to 3.40% by Q4.

Strategic Balance Sheet Optimization Management executed a three-pronged strategy involving a $2.3 billion securities repositioning, an $825 million targeted loan sale, and $385 million in subordinated debt retirement to remove 'weights' hindering franchise earnings power. The securities repositioning replaced lower-yielding (2.1%) long-duration assets with higher-yielding (4.87%) shorter-duration instruments, generating a 276 basis point yield pickup.

Banc of California reported a 2Q net loss of $251.3 million, or $1.61 per share, after restructuring its balance sheet. The bank sold $2.3 billion of securities, redeployed $1.7 billion into higher-yield shorter-duration holdings, initiated $827 million of commercial real estate and multifamily loan sales, and retired $385 million of subordinated debt. It expects to complete loan sales in 3Q and target higher recurring earnings.

BANC OF CALIFORNIA, INC. (BANC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991_063026er.htm EX-99.1 EX99.1_06.30.26 ER 1 Second Quarter 2026 Results Press Release Banc of California, Inc. Reports Second Quarter 2026 Financial Results and Announces Strategic Balance Sheet Repositioning to Enhance Long-Term Earnings Company Release – 7/29/2026

Canadian Banc Corp. said the TSX accepted its notice for a Normal Course Issuer Bid to repurchase Preferred Shares and Class A Shares. The NCIB runs June 3, 2026 to June 2, 2027. It may buy up to 5,519,308 Preferred and 5,340,328 Class A shares (10% of public float), with a 30-day cap of 2%. Shares repurchased will be cancelled.

Takeda (TYO:4502/NYSE:TAK) announced Japan's approval of ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The drug, discovered by Takeda, is the first to target the underlying cause of NT1. Approval follows successful Phase 3 trials showing significant symptom improvements. ORZEYFUL is also approved in China and the U.S.